A 24,000-compound screen in giant plasma membrane vesicles (GPMVs) identified five first-in-class small molecules that modulate ordered membrane domains (lipid rafts) and protein partitioning into them: two protein-enhanced raft destabilizers (VU0615562, VU0619195) and three protein-independent modulators (VU0519975, VU06107402, and primaquine diphosphate). The exact molecular mechanisms by which these compounds act remain unestablished. Published follow-up work by the discovering group has proposed mechanistic models — a dual lipid-lipid/protein-lipid disruption mode for the protein-enhanced compounds, supported by weak nonspecific NMR-detected interactions with the raft-preferring protein PMP22 and with the TRPM8 voltage-sensor-like domain, and lipid-packing alteration for the protein-independent compounds — but explicitly requires further studies to confirm them. Lipidomic analyses have not been performed to rule out changes in membrane lipid composition, cellular homeostatic responses to chronic exposure are uncharacterized, and the use of these compounds in cell types beyond the screened lines, or across broad classes of membrane proteins thought to be raft-dependent versus raft-independent, is untested. The problem is to establish these mechanisms and delineate the validated scope of these compounds as pharmacological probes of ordered membrane domains.

Background

Lipid rafts are nanoscale-to-microscale ordered domains in cell plasma membranes, enriched in cholesterol and sphingolipids, that are widely proposed to organize signaling proteins; their study has long been hampered by a lack of pharmacological tools that manipulate rafts without broadly damaging the membrane (the classical tool methyl-beta-cyclodextrin, MBCD, physically extracts cholesterol and is cytotoxic). Giant plasma membrane vesicles (GPMVs) are cell-derived blebs that retain the protein and lipid composition of the plasma membrane but undergo macroscopic liquid-liquid phase separation into ordered (raft-like) and disordered phases upon cooling, allowing quantitative measurement of raft stability and of the partitioning of fluorescently tagged proteins between the phases (reported as the fraction in the ordered phase, P-ordered). Peripheral myelin protein 22 (PMP22), a tetraspan membrane protein of myelin, and MAL (myelin and lymphocyte protein), an unrelated tetraspan raft-associated protein, are among the few multipass transmembrane proteins rigorously shown to preferentially partition into ordered domains in GPMVs, which made them suitable readouts for a compound screen. Stefanski et al. screened 24,000 small molecules for modulators of PMP22 raft affinity in GPMVs, counter-screened against MAL, and found five tool compounds in two classes. Class I compounds (VU0615562 and VU0619195) shift PMP22 and MAL toward the disordered phase and reduce raft formation in a manner enhanced by the presence of these raft-preferring proteins; Class II compounds (VU0519975, VU06107402, whose identifier is printed as VU0607402 in the published Communications Chemistry version of the same work, and the stabilizer primaquine diphosphate) modulate raft formation independently of these proteins, apparently by altering lipid-lipid interactions and membrane fluidity. Both classes acutely alter membrane fluidity in live cells and modulate raft-sensitive proteins such as the cold-sensing ion channel TRPM8. The original preprint left all mechanisms open, and its discovery was subsequently published in two peer-reviewed papers: the Class II compounds in Communications Chemistry (2026) and the Class I compounds in PNAS (2026). The PNAS paper provides the first direct interaction evidence for the Class I compounds: NMR-monitored titrations show weak, nonspecific interactions with PMP22 that perturb residue R159 (part of a putative cholesterol-binding CRAC motif, a short protein sequence motif that binds cholesterol) and additional residues, and similar weak interactions with the TRPM8 voltage-sensor-like domain; protein-free large unilamellar vesicles (LUVs; spherical single-bilayer model membranes) also show fluidity changes, so the compounds' activity is enhanced by, but not entirely dependent on, raft-preferring proteins. Based on this, a dual mechanism was proposed: the compounds' peripheral aromatic moieties partition near the membrane headgroup region and preferentially disrupt ordered-phase lipid-lipid interactions, while their shared 1,2,3-triazole core (a chemical group known to act as a hydrogen-bond acceptor toward proteins) engages polar interfacial residues of raft-preferring proteins nonspecifically, interfering with raft-stabilizing protein-lipid interactions including cholesterol binding. A further physical context for the problem is that cells homeostatically maintain their membranes near the miscibility critical point (the temperature-composition condition at which ordered and disordered phases become miscible), adjusting membrane composition in response to temperature changes, so chronic pharmacological perturbation of raft stability is expected to evoke compensatory remodeling whose extent and time course are unknown.

Problem Statement

Establish the molecular mechanisms by which the five small-molecule modulators of ordered membrane domains discovered by Stefanski et al. act, and determine the validated scope of their use as raft probes. Concretely: (1) for the protein-enhanced Class I compounds VU0615562 and VU0619195, provide direct evidence confirming, refining, or refuting the proposed dual mechanism — preferential disruption of ordered-phase lipid-lipid interactions by the compounds' peripheral aromatic moieties plus nonspecific interfacial interactions of the 1,2,3-triazole core with raft-preferring proteins (observed at PMP22 residue R159 and in the TRPM8 voltage-sensor-like domain) that interfere with raft-stabilizing protein-lipid and protein-cholesterol interactions — including deciding whether the protein-enhanced activity reflects direct compound-protein engagement or protein-expression-induced changes in membrane composition; (2) for the protein-independent Class II compounds VU0519975, VU06107402, and primaquine diphosphate, confirm or refute the proposed model that they act by altering lipid-lipid interactions and membrane packing rather than by changing membrane lipid composition, using lipidomic analyses to rule out composition changes at the short incubation times tested; (3) characterize the extent and time course of homeostatic membrane remodeling and cellular adaptation when live cells are exposed to these compounds over long periods, given cellular mechanisms that maintain membranes near the miscibility critical point; and (4) establish whether the compounds can be used to study raft-dependent phenomena in cell types beyond those tested and across broad classes of membrane proteins thought to be raft-dependent versus raft-independent. All four strands are jointly required: the task is resolved only when each of (1)-(4) has been addressed, and resolving any proper subset of the strands — for example strand (1) alone, or strands (1)-(2) — does not by itself resolve it. These strands jointly serve one objective: converting the phenomenological raft-modulating activity of these first-in-class tool compounds into a mechanistically grounded account of how lipid-lipid and protein-lipid forces stabilize ordered membrane domains and how each can be pharmacologically manipulated, so that experiments using these compounds can be interpreted in terms of a specified physical mechanism.

References

  1. Katherine M. Stefanski, Hui Huang, Dustin D. Luu, James M. Hutchison, Nilabh Saksena, Alexander J. Fisch, Thomas P. Hasaka, Joshua A. Bauer, Anne K. Kenworthy, Wade D. Van Horn, Charles R. Sanders. Small-Molecule Modulators of Lipid Raft Stability and Protein-Raft Partitioning. bioRxiv preprint (2024), doi:10.1101/2024.10.28.620521, https://doi.org/10.1101/2024.10.28.620521
  2. Katherine M. Stefanski, Hui Huang, Dustin D. Luu, Geoffrey C. Li, James M. Hutchison, Nilabh Saksena, Alexander J. Fisch, Thomas P. Hasaka, Joshua A. Bauer, Anne K. Kenworthy, Wade D. Van Horn, Charles R. Sanders. Pharmacological tools to modulate ordered membrane domains and order-dependent protein function. Communications Chemistry 9, 72 (2026), doi:10.1038/s42004-025-01874-8, https://doi.org/10.1038/s42004-025-01874-8
  3. Katherine M. Stefanski, Geoffrey C. Li, Dustin D. Luu, Kelvin K. Fosu, Eduardo Guadarrama, James M. Hutchison, Nilabh Saksena, Yelyzaveta Zuy, Alexander J. Fisch, Thomas P. Hasaka, Joshua A. Bauer, Alfred L. George, Anne K. Kenworthy, Wade D. Van Horn, Charles R. Sanders. Protein-enhanced small molecule disruptors of ordered membrane domains. Proceedings of the National Academy of Sciences 123, e2530579123 (2026), doi:10.1073/pnas.2530579123, https://doi.org/10.1073/pnas.2530579123
  4. Justin T. Marinko, Anne K. Kenworthy, Charles R. Sanders. Peripheral myelin protein 22 preferentially partitions into ordered phase membrane domains. Proceedings of the National Academy of Sciences 117, 14168-14177 (2020), doi:10.1073/pnas.2000508117, https://doi.org/10.1073/pnas.2000508117
  5. Ivan Castello-Serrano, Joseph H. Lorent, Rossana Ippolito, Kandice R. Levental, Ilya Levental. Myelin-Associated MAL and PLP Are Unusual among Multipass Transmembrane Proteins in Preferring Ordered Membrane Domains. The Journal of Physical Chemistry B 124, 5930-5939 (2020), doi:10.1021/acs.jpcb.0c03028, https://doi.org/10.1021/acs.jpcb.0c03028
  6. Nico Fricke, Krishnan Raghunathan, Ajit Tiwari, Katherine M. Stefanski, Muthuraj Balakrishnan, Alex G. Waterson, Ricardo Capone, Hui Huang, Charles R. Sanders, Joshua A. Bauer, Anne K. Kenworthy. High-Content Imaging Platform to Discover Chemical Modulators of Plasma Membrane Rafts. ACS Central Science 8, 370-378 (2022), doi:10.1021/acscentsci.1c01058, https://doi.org/10.1021/acscentsci.1c01058